Results 31 to 40 of about 5,044 (130)

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

open access: yesCancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer   +3 more
wiley   +1 more source

Regulation of human CYP2C9 expression by electrophilic stress involves AP-1 activation and DNA looping [PDF]

open access: yes, 2014
CYP2C9 and CYP2C19 are important human enzymes that metabolize therapeutic drugs, environmental chemicals and physiologically important endogenous compounds.
Goldstein, J. A.   +4 more
core   +1 more source

Alcohol Dehydrogenase 4‐Mediated Retinol Metabolism Inhibits Hepatocellular Carcinoma Progression Through Inhibiting the Wnt/β‐Catenin Pathway

open access: yesMedComm – Oncology, Volume 4, Issue 2, June 2025.
The downregulation of ADH4 expression induces hepatocyte apoptosis, thereby contributing to liver fibrosis and the initiation of hepatocellular carcinoma (HCC). Moreover, sustained suppression of ADH4 in HCC cells disrupts retinoic acid synthesis, leading to reduced expression of the Wnt/β‐catenin signaling inhibitor WIF‐1 via RARs/RXRs‐mediated ...
Jiaying Li   +10 more
wiley   +1 more source

Genetic Variation in the CYP2C Monooxygenase Enzyme Subfamily Shows No Association With Longevity in a German Population [PDF]

open access: yes, 2017
Cytochrome P450 enzymes, especially the CYP2C subfamily, are involved in the generation of reactive oxygen species and are regarded as susceptibility factors for age-related diseases.
Flachsbart, Friederike   +5 more
core  

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis [PDF]

open access: yes, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Chiara Tommasi   +8 more
core   +2 more sources

Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis

open access: yesUnited European Gastroenterology Journal, Volume 13, Issue 5, Page 719-727, June 2025.
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO).
Anita Afzali   +12 more
wiley   +1 more source

Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics [PDF]

open access: yes, 2017
Adverse reactions or lack of response to medications are important concerns for drug development programs. However, faithful predictions of drug metabolism and toxicity are difficult because animal models show only limited translatability to humans ...
Beck, Olof   +7 more
core   +1 more source

In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers

open access: yesThe Journal of Clinical Pharmacology, Volume 65, Issue 4, Page 508-519, April 2025.
Abstract Fezolinetant is an oral, nonhormonal, neurokinin 3 receptor antagonist treatment option for moderate to severe vasomotor symptoms associated with menopause. An in vitro study using human recombinant cytochrome P450 (CYP) enzymes and human liver microsomes showed that fezolinetant is metabolized to its major but inactive metabolite, ES259564 ...
Megumi Iwai   +8 more
wiley   +1 more source

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class [PDF]

open access: yes, 2016
New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition potential before consumption. Therefore, this potential was explored for tryptamine-derived NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl ...
Brandt, SD   +4 more
core   +1 more source

Functional Imaging of CYP3A4 at Multiple Dimensions Using an AI‐Driven High Performance Fluorogenic Substrate

open access: yesSmall, Volume 21, Issue 17, April 28, 2025.
This study showcases a novel artificial intelligence (AI)‐driven design strategy for constructing highly specific and orally‐active fluorogenic substrates for imaging CYP3A4 in complex biological systems, while NFa emerged as a practical and reliable tool for sensing and imaging of CYP3A4 activity thus facilitating CYP3A4‐associated fundamental ...
Feng Zhang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy